Amani M. Ali

Amani M. Ali

Auto-generated profile, based on publicly available information

Amani M. Ali


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 August 2025 in BMC Gastroenterology
Verified
Journal Article
Open access
PDF file
AAAmani M. Ali
Amani M. Ali
MAMohamed Abdelrahim
Mohamed Abdelrahim
AAAya M. AbdelMagid
Aya M. AbdelMagid
Background: Autoimmune hepatitis (AIH) is a chronic progressive inflammatory liver disease of immune-mediated origin, which causes long-term liver inflammation and damage. Traditionally, treatment includes azathioprine (AZA) combined with steroids, but recent studies have highlighted mycophenolate mofetil (MMF) as a potential alternative, particularly for patients who do not respond well to AZA. Aims: This study aimed to evaluate the efficacy and safety of MMF versus AZA combined with steroids as first-line treatment for the management of AIH patients. Methods: A comprehensive systematic review was conducted using the keywords: mycophenolate mofetil, Cellcept, and autoimmune hepatitis. Studies comparing MMF to AZA combined with steroids in treatment-naïve patients with AIH were included. Efficacy was assessed based on complete biochemical remission (CBR), non-response, and relapse rates. Safety was evaluated on the basis of the incidence of serious adverse effects that led to treatment discontinuation. Statistical analysis included calculation of odds ratios (OR) and 95% confidence intervals (CI). Results: Out of 344 search results, four studies met the inclusion criteria, encompassing a total of 512 patients. MMF combined with prednisolone significantly improved both short-term CBR rates (OR, 2.56; 95% CI, 1.18–5.55) and long-term CBR rates (OR, 5.51; 95% CI, 1.7–17.91) compared to AZA combined with prednisolone. Furthermore, MMF treatment was associated with a significantly lower occurrence of serious adverse events (OR, 0.15; 95% CI, 0.07–0.34). Conclusions: Compared to AZA-based regimens, MMF-based first-line therapy for AIH appears to be a more promising, effective, and safe treatment option, yielding higher CBR rates and fewer serious adverse events requiring treatment discontinuation.

1 May 2017 in Annals of Allergy, Asthma & Immunology
Verified
Journal Article
Closed access
AAAmani M. Ali
Amani M. Ali
SSSamah Selim
Samah Selim
MAMaggie M. Abbassi
Maggie M. Abbassi
NSNirmeen A. Sabry
Nirmeen A. Sabry

8 August 2023 in European Journal of Nutrition
Verified
Journal Article
Open access
PDF file
AAAmani M. Ali
Amani M. Ali
MAMaggie M. Abbassi
Maggie M. Abbassi
NSNirmeen A. Sabry
Nirmeen A. Sabry
MFMay Fawzi
May Fawzi
SMShrook Mousa
Shrook Mousa
Purpose: The purpose of this study was to assess the possible clinical effects of vitamin K4 supplementation in individuals with type 2 diabetes namely insulin resistance, glycaemic control, and lipid profile. Methods: This was a prospective randomised double-blind placebo-controlled clinical trial. A total of 106 patients were randomised to receive either 1 mg of vitamin K4 (menadiol diacetate) or placebo for 24 weeks. Results: Ninety patients (n = 45 in each study group) were included in the final analysis. After 24 weeks, homeostatic model assessment of insulin resistance (HOMA-IR) (16.54 ± 7.81 vs. 29.09 ± 36.56, P = 0.027) and fasting serum insulin (FSI) (6.86 ± 3.45 vs. 11.13 ± 12.66 µU/ml, P = 0.032) were significantly lower in the vitamin K group compared to placebo. Additionally, triglycerides (TG) (144.94 ± 50.7 vs. 172.8 ± 101.5 mg/dl, P = 0.031) and very low-density lipoproteins (VLDL) levels (28.9 ± 9.88 vs. 34.6 ± 20.30 mg/dl, P = 0.027) decreased significantly in the vitamin K group after 24 weeks compared to baseline. Moreover, more patients in the vitamin K group (35.6%) had their antidiabetic medication doses reduced after 24 weeks compared to placebo (13.3%, P = 0.029). Conclusion: Vitamin K4 supplementation for 24 weeks is capable of improving insulin resistance and TG levels in individuals with type 2 diabetes. In addition, the improvement in insulin resistance was reflected in the decrease in antidiabetic medication doses. However, it did not affect fasting plasma glucose (FPG) or glycated haemoglobin (HbA1c). Trial registration: The study was registered on clinicaltrials.gov with ID: NCT04285450.

5 May 2026 in npj Digital Medicine
Verified
Journal Article
Open access
AFAhmed N. Farrag
Ahmed N. Farrag
AEAmany El-Zeiny
Amany El-Zeiny
AAAmani M. Ali
Amani M. Ali
Simulation-based learning is essential in clinical pharmacy education but requires substantial faculty resources that limit scalability. Large language models (LLMs) offer promise for generating scalable simulations, yet their pedagogical rigor and clinical reliability remain unclear. In a mixed-methods, counterbalanced evaluation study, PharmD students ( n = 104) engaged with acute myeloid leukemia (AML) or chronic myeloid leukemia (CML) cases, conditions requiring complex longitudinal management yet sharing semantic similarity, generated by four LLMs using expert-guided meta-prompts. Expert panels evaluated sessions across clinical authenticity, instructional design, and clinical reasoning; students completed satisfaction surveys. Of 103 sessions, 53 (51.5%) met passing criteria across all domains. Clinical accuracy and safety emerged as the limiting domain (58.3%) compared to clinical reasoning (81.6%) and instructional design (82.5%). CML sessions outperformed AML sessions (62.3% vs 40.0%; p = 0.031). Platform success rates ranged from 34.5% to 62.1%. Error analysis revealed guideline misalignment, pharmacotherapeutic inaccuracies, fabricated evidence, and cross-condition therapeutic recommendations occurring exclusively in AML sessions. Students favored LLMs over traditional methods (49.8% vs 30.0%); however, we did not detect statistically significant alignment between student satisfaction and expert-assessed quality. Sessions more frequently met criteria for instructional design and clinical reasoning than for pharmacotherapeutic accuracy and guideline alignment. Expert oversight with platform-specific and disease-specific validation remains essential for safe educational deployment, and effectiveness trials assessing objective learning outcomes represent necessary subsequent work.

16 March 2026 in Arab Journal of Gastroenterology
Verified
Journal Article
Closed access
RMRahma Mohamed
Rahma Mohamed
AAAya M. Abdelmagid
Aya M. Abdelmagid
AAAmani M. Ali
Amani M. Ali
AKAhmed M Kamel
Ahmed M Kamel
ACAhmed Cordie
Ahmed Cordie

12 October 2026 in Journal of Clinical Apheresis
Verified
Journal Article
Closed access
EMEman A. Makhlouf
Eman A. Makhlouf
SFSalma M. Abdel Fattah
Salma M. Abdel Fattah
NANoha T. Abokrysha
Noha T. Abokrysha
AAAmani M. Ali
Amani M. Ali